P153 Associates of, and time to recovery from, eosinopenia in severe exacerbation of COPD (A-TREC)
No Thumbnail Available
Authors
Bourke, Stephen
Steer, John
Prasad, Arun
Ireland, Peter
Mussell, G
Scott, M
Issue Date
2023
Type
Article
Language
en
Keywords
Alternative Title
Abstract
Introduction
Blood eosinophil count (BEC) guides selection for inhaled corticosteroid (ICS) and emerging biologics in COPD. Neither GOLD nor NICE specify measuring BEC during clinical stability. 50% of patients admitted with severe exacerbation of COPD have transient eosinopenia (BEC <50 cells/uL).1
Aims
This preliminary analysis from the A-TREC study (clinicaltrials.gov NCT06188065) examines time to recovery in BEC in the subgroup with admission eosinopenia and an uneventful recovery; this will not alter target recruitment. We aim to recruit 200 patients to identify 69 with admission eosinopenia and an uneventful recovery.
Methods
atients with a severe exacerbation of COPD and admission eosinopenia were assessed with measurement of BEC on days 3, 7, 14, 21, 28 and 42 following admission. Patients with an eventful recovery (further systemic corticosteroids or emergency hospital admission during follow up) were excluded. Stable-state was defined as day 42 BEC.
Description
Citation
Bourke, S., Steer, J., Prasad, Arun. et al. (2023) P153 Associates of, and time to recovery from, eosinopenia in severe exacerbation of COPD (A-TREC). Thorax Journal; 80 : A234
Publisher
License
Journal
Thorax